Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Monday reported positive long-term data for mirikizumab, an IL-23p19 antagonist, in treating ulcerative colitis (UC) and Crohn's disease.

In UC patients, mirikizumab maintained long-term remission, mucosal healing and symptom relief for up to three years. Similarly, in Crohn's disease patients, the drug sustained clinical and endoscopic remission for up to five years.

These findings highlight mirikizumab's potential as a long-term treatment option for inflammatory bowel disease (IBD) patients, addressing a significant unmet need. The drug is currently approved for UC in the United States and is under regulatory review for Crohn's disease.